Home > News > featured news > Activated PMN exosomes are pathogenic entities that cause destruction in the COPD lung

Activated PMN exosomes are pathogenic entities that cause destruction in the COPD lung

Medical XPress | January 11, 2019

The University of Alabama at Birmingham researchers have found a novel, previously unreported pathogenic entity that is a fundamental link between chronic inflammation and tissue destruction in the lungs of patients with chronic obstructive pulmonary disease, or COPD. COPD is the fourth-leading cause of death in the world.
This pathogenic entity—exosomes from activated polymorphonuclear leukocytes, or PMNs—caused COPD damage when the small, subcellular particles, collected from purified PMNs, were instilled into the lungs of healthy mice. Remarkably, the UAB researchers also collected exosomes from the lung fluids of human patients with COPD and the lung fluids of neonatal ICU babies with the lung disease bronchopulmonary dysplasia; when those human-derived exosomes were instilled into the lungs of healthy mice, they also caused COPD lung damage. Damage was primarily from PMN-derived exosomes from the human lungs.

Spotlight

A History of Approved Therapeutic Antibodies

As medicine progresses into a new era of personalized therapy, therapeutic antibodies are leading the charge and have grown into a billion-euro industry. Antibodies present an attractive option for a wide variety of common diseases because of their specificity and flexibility. Major blockbusters like Humira, Remicade, MabThera, Avastin, and Herceptin are therapeutic antibodies, which represent today the fastest growing group of biotechnology-derived molecules in clinical trials.

More featured news

Spotlight

A History of Approved Therapeutic Antibodies

Related News

MEDICAL

Zynex Recognized as Fourth Largest Biotechnology/Bioscience Company in Colorado

Zynex, Inc. | March 24, 2022

Zynex, Inc. (Nasdaq: ZYXI) an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced the Denver Business Journal has recognized Zynex as the fourth largest Biotechnology/Bioscience public company in Colorado based on number of companywide employees as of November 1, 2021. 2021 was a strong year for us with growth on the top and bottom lines, In 2022, we expect sales rep growth and productivity to improve and are seeing momentum in order growth as the economy normalizes post COVID-19. We are positioned for another solid year of revenue growth." Thomas Sangaard, CEO and founder of Zynex Inc. About Denver Business Journal American City Business Journals (ACBJ) is the largest publisher of metropolitan business newsweeklies in the United States, with 44 business publications across the country reaching more than 3.6 million readers each week. About Zynex, Inc. Zynex, founded in 1996, develops, manufactures, markets and sells medical devices used for pain management and rehabilitation as well as non-invasive fluid, sepsis and laser-based pulse oximetry monitoring systems for use in hospitals.

Eurofins Discovery Announces Collaboration with a Swiss-based Biotech Company Amphilix AG

Eurofins Discovery | November 04, 2020

Eurofins Discovery, the leading provider of services and products to the drug discovery industry, announced a new collaboration with Amphilix AG, a Swiss-based biotech company, to support a program aimed at identifying a treatment modulating key disease mechanisms. Amphilix AG will take advantage of Eurofins Discovery's DiscoveryOne™ offering, an integrated drug discovery platform providing expert support to progress programs to preclinical development and beyond. Amphilix will engage Eurofins Discovery to prosecute the biology, pharmacology, ADME, and safety pharmacology aspects of the program, working in collaboration with the accomplished team at Eurofins Discovery to progress to a development candidate. The two organizations expect this to be the first of multiple programs in which they collaborate to discover new treatments for unmet medical needs.

CELL AND GENE THERAPY

Mekonos Raises $4.6M Financing Round for Targeted Ex Vivo Gene Engineering

Mekonos | November 24, 2020

Mekonos, a biotech organization launching the first-of-its kind system-on-a-chip (SoC) for focused ex vivo gene engineering, today reported it has finished a $4.6 million financing round. Mekonos will utilize the new funding to quicken the SoC stage for its current and new ad organizations. The SoC stage, with IP from Stanford University, is a breakthrough that allows for molecular delivery in gene editing and synthetic biology. The stage is versatile over all cell types and has demonstrated to be a high return answer for partners. The stage assists organizations with expanding limit, quicken revelations, and develop new pre-clinical assets in the emerging cell and gene therapy space. The financing round was driven by Novartis AG with participation from institutional VCs including Hike Ventures, CRCM Ventures. Existing investors participated in the round, including Good AI Capital and past lead Elementum Ventures.